Genentech is investing $750 million in a new drug delivery device facility at its Hillsboro, Oregon site, aimed at expanding manufacturing capacity for delivery technologies. In parallel, Bavarian Nordic delayed a Lyme trial, signaling schedule variability for infectious-disease development despite continued operational capital spending elsewhere in the Roche group.